Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Overweight or Obesity
NCT07665879Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Eloralintide with Placebo (2 arms). Primary endpoint: Hyperinsulinemic Euglycemic Clamp Predicted Clamp-Derived Insulin Sensitivity at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07665879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665879.